Updated Interim Results from PBCAR0191’s Ph1/2a Trial; New Details Provided for PBCAR19B Stealth CAR-T Program; Precision’s Pre-ASCO CD19 Event
On Friday, June 4, Precision BioSciences held their PBCAR0191 CD19 virtual update event (webcast / presentation). Management reported updated results on PBCAR0191’s Ph1/2a trial in r/r NHL while providing further details on their CD19 stealth cell program (PBCAR19B). Below, Celltelligence provides insights on the effect of Precision’s enhanced lymphodepletion (eLD) regimen to improve PBCAR0191’s efficacy while comparing PBCAR0191’s dosing strategy and lymphodepletion approach with key competitor Allogene.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.